ClinicalTrials.gg
Not yet recruitingNCT07210749Updated Oct 13, 2026

Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma

An interventional study of External Beam Radiation Therapy in Orbital Lymphoma, sponsored by British Columbia Cancer Agency. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by British Columbia Cancer Agency · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities. Ultra-low dose RT (4Gy in 2 fractions) has minimal toxicity but lower disease control, requiring intensive follow-up to salvage persistent tumors. Some centers are moving towards this dose as the new standard. A recent study using 12Gy in 4 fractions to any body site showed early data suggesting high disease control rates with minimal toxicity. This study assesses 12Gy in 6 fractions, aiming to enhance disease control over 4Gy while reducing toxicity compared to 24Gy.

02

Conditions studied

  • Orbital Lymphoma
03

In context

Lead sponsor

British Columbia Cancer Agency is the lead sponsor of 153 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years with stage I-IV indolent NHL*
  • Able to provide
  • confirmed indolent NHL involving one or both orbits. If bilateral, of only one orbit is permitted as long as high clinical suspicion of contralateral orbit involvement
  • Measurable orbital disease after biopsy, either clinically or radiographically
  • performance status 0-3
  • >12 months
  • Available for treatment and follow-up (including scheduled post-treatment imaging and ophthalmologic exam)
  • Able and willing to complete quality of life questionnaires via paper or online portal if they provide their email address on the informed consent document

    • Stage II-IV allowed but if systemic therapy given after RT the timing will be recorded, and subjects will be stratified according to receipt of systemic therapy

Exclusion criteria

Exclusion Criteria:

  • Aggressive NHL histology (including grade 3B follicular lymphoma)
  • Prior RT to orbit
  • Patients requiring treatments outside standard clinical hours
  • Systemic therapy for lymphoma is not permitted within the period of time between 2 weeks prior to RT start and 2 weeks after RT completion
  • Patients who are pregnant
  • History of other within 5 years prior to screening, with the exception of those with a negligible risk of or death and/or treated with expected curative outcome (for example, appropriately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, localized prostate cancer, breast ductal carcinoma in-situ, or stage I endometrial cancer)
  • Any medical condition that, in the investigator's judgement, would preclude the individual's safe participation in and completion of the study, or could affect interpretation of the results (e.g. pre-existing retinopathy, active connective tissue disease)
  • Inability to comply with study and follow-up procedures
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    12 Gy in 6 fractions of external beam radiation therapy

    12 Gy in 6 fractions of conventional external beam radiation therapy using standard-of-care radiation volumes for low-grade orbital lymphoma

    Radiation: External Beam Radiation Therapy

Interventions

  • RadiationExternal Beam Radiation Therapy

    12 Gy in 6 fractions of external beam radiation therapy

06

What researchers measure

Primary outcomes

  1. Assess 2-year orbital LC after 12 Gy in 6 fractions.

    Time frame: 24 Months after Treatment

Secondary outcomes

  1. Response rates (complete/partial/minimal response, stable/progressive disease)

    Time frame: 6 months and 12 months after treatment

  2. Evaluate orbital local control

    Time frame: 5 years after treatment

  3. Assess freedom from further in-field RT (FFRT), freedom from distant relapse (FFDR) and overall survival (OS)

    Time frame: 2 year and 5 year after treatment

  4. Health-Related Quality of Life using the EORTC QLQ-C30

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) measures health-related quality of life through 5 functional, 9 symptom, and 1 global health status scale; minimum score = 0, maximum score = 100 (for functional scales, higher is better; for symptom scales, lower is better)

    Time frame: 5 years after treatment

  5. Ocular Toxicity per CTCAE (5.0)

    Time frame: 2 year and 5 year after treatment

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Aug 2035, 104 months later.

Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Dec 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Oct 7, 2025
StartEst.
Dec 1, 2026was Nov 2025
Primary completionEst.
Aug 31, 2035
CompletionEst.
Aug 31, 2036
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2025→Dec 1, 2026
Oct 13, 2026
Contact
Study contact changed: s•••@bccancer.bc.ca · •••4100→f•••@bccancer.bc.ca · •••6000. See the current contact
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Nov 1, 2025→Dec 1, 2026
    Contact Study contact changed: s•••@bccancer.bc.ca · •••4100→f•••@bccancer.bc.ca · •••6000. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07210749
Responsible party
Matthew Chan (Principal Investigator (Co-PI), British Columbia Cancer Agency) — Principal investigator
First posted
Oct 7, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 31, 2035 (estimated)
Completion
Aug 31, 2036 (estimated)
Last update
Oct 13, 2026

Study contacts

Fermin Hoq
Contact
fermin.hoq1@bccancer.bc.ca
604-877-6000 ext. 675076

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion